Get the Stockscreener App
44.94
2.39%
-1.10
Pre-market:
40.60
-4.34
-9.66%
Kiniksa Pharmaceuticals International Plc stock is traded at $44.94, with a volume of 402.31K.
It is down -2.39% in the last 24 hours and up +3.31% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
See More
Previous Close:
$46.04
Open:
$45.75
24h Volume:
402.31K
Relative Volume:
0.66
Market Cap:
$3.44B
Revenue:
$677.56M
Net Income/Loss:
$59.01M
P/E Ratio:
60.30
EPS:
0.7453
Net Cash Flow:
$136.42M
1W Performance:
-4.42%
1M Performance:
+3.31%
6M Performance:
+24.52%
1Y Performance:
+91.97%
1-Day Range:
$44.43
$45.75
1-Week Range:
$44.36
$47.16
52-Week Range:
$18.25
$49.12
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
44.94 | 3.44B | 677.56M | 59.01M | 136.42M | 0.7453 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Canaccord Genuity | Buy |
| Sep-29-25 | Initiated | TD Cowen | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
If You Invested $1,000 in Kiniksa Pharmaceuticals International, plc (KNSA) - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a High-Growth Momentum Setup - ChartMill
Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance - MSN
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top GARP Investment - ChartMill
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Pullback - Yahoo Finance
Kiniksa Pharmaceuticals International, plc Q4 2025 earnings preview - MSN
Kiniksa Pharmaceuticals International PLC (KNSA) Stock Price Up 3.67% on Mar 16 - GuruFocus
Granahan Investment Management LLC Sells 27,421 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by ArrowMark Colorado Holdings LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Acquires 101,666 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
FMR LLC's Strategic Acquisition of Kiniksa Pharmaceuticals Shares - GuruFocus
Kiniksa (KNSA) CFO sells 36,722 shares after exercising options - Stock Titan
Kiniksa (NASDAQ: KNSA) insider sale notice lists 36,722 shares (Rule 144) - Stock Titan
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going - MSN
FMR LLC holds 10.6% of Kiniksa (KNSA) — 4.85M shares reported - Stock Titan
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again - MSN
Vanguard Group Inc. Trims Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and Bullish Chart Setup - ChartMill
Fisher Asset Management LLC Acquires 180,029 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals CMO Sells Shares Worth Nearly $1.8 Million - TradingView
Kiniksa Pharmaceuticals (KNSA) CMO sells 40K shares after option exercise - Stock Titan
How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility - simplywall.st
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Robust Growth Potential With 23% Upside - DirectorsTalk Interviews
Kiniksa (NASDAQ: KNSA) Rule 144 notice: 40,000-share cashless exercise - Stock Titan
KNSA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Prime Example of Affordable Growth (GARP) Investing - ChartMill
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Volatility - Yahoo Finance
KNSA/N Stock Price and Chart — BIVA:KNSA/N - TradingView
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewswire
The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts - Benzinga
KNSA: Wells Fargo Raises Price Target and Maintains Overweight R - GuruFocus
KNSA: Wedbush Raises Price Target to $53, Maintains Outperform R - GuruFocus
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Compelling Value Investment - ChartMill
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Biopharma's Strong Growth Trajectory And 17.9% Upside Potential - DirectorsTalk Interviews
Pharma firm Kiniksa offers live March 2 TD Cowen health care chat - Stock Titan
Kiniksa outlines $900M–$920M 2026 ARCALYST revenue guidance as market penetration deepens - MSN
Beyond the Balance Sheet: What SWOT Reveals About Kiniksa Pharma - GuruFocus
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Kiniksa (KNSA) Q4 2025 Earnings Call Transcript - The Globe and Mail
Kiniksa Pharmaceuticals International, plcClass A Ordinary Shares (NQ: KNSA - The Chronicle-Journal
Kiniksa Pharmaceuticals International PLC (KNSA) Q4 2025 Earning - GuruFocus
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 49.12 - Markets Mojo
Kiniksa Pharmaceuticals International Q4 Earnings Call Highlights - Yahoo Finance
Kiniksa Pharmaceuticals: A Multibagger with 140.68% Return and Strong Financial Metrics - Markets Mojo
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Down 6.3% on Feb 24 - GuruFocus
Kiniksa Pharmaceuticals International, plc 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KNSA) 2026-02-24 - Seeking Alpha
Wedbush Adjusts Kiniksa Pharmaceuticals International Price Target to $53 From $50, Maintains Outperform Rating - marketscreener.com
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):